Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
The AML1/ETO and PML/RARalpha leukemia fusion proteins induce acute myeloid leukemia by acting as transcriptional repressors. They interact with corepressors, such as N-CoR and SMRT, that recruit a multiprotein complex containing histone deacetylases on crucial myeloid differentiation genes. This leads to gene repression contributing to generate a differentiation block. We expressed in leukemia cells containing PML/RARalpha and AML1/ETO N-CoR protein fragments derived from fusion protein/corepressor interaction surfaces. This blocks N-CoR/SMRT binding by these fusion proteins, and disrupts the repressor protein complex. In consequence, the expression of genes repressed by these fusion proteins increases and differentiation response to vitamin D3 and retinoic acid is restored in previously resistant cells. The alteration of PML/RARalpha-N-CoR/SMRT connections triggers proteasomal degradation of the fusion protein. The N-CoR fragments are biologically effective also when directly transduced by virtue of a protein transduction domain. Our data indicate that fusion protein activity is permanently required to maintain the leukemia phenotype and show the route to developing a novel therapeutic approach for leukemia, based on its molecular pathogenesis.
Racanicchi
Serena
S
Patologia Generale and Medicina Interna e Scienze Oncologiche, Dipartimento di Medicina Clinica e Sperimentale, Perugia University, Policlinico Monteluce, Perugia, Italy.
Maccherani
Chiara
C
Liberatore
Concetta
C
Billi
Monia
M
Gelmetti
Vania
V
Panigada
Maddalena
M
Rizzo
Giovanni
G
Nervi
Clara
C
Grignani
Francesco
F
D000208:Acute Disease; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D002762:Cholecalciferol / Q000494:pharmacology; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D056971:Nuclear Receptor Co-Repressor 1; D056985:Nuclear Receptor Co-Repressor 2; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism*; D010455:Peptides / Q000235:genetics / Q000502:physiology; D017434:Protein Structure, Tertiary / Q000235:genetics / Q000502:physiology; D000075142:RUNX1 Translocation Partner 1 Protein; D012097:Repressor Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology
C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; C539127:NCOR1 protein, human; C539130:NCOR2 protein, human; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D056971:Nuclear Receptor Co-Repressor 1; D056985:Nuclear Receptor Co-Repressor 2; D015514:Oncogene Proteins, Fusion; D010455:Peptides; D000075142:RUNX1 Translocation Partner 1 Protein; D012097:Repressor Proteins; D014157:Transcription Factors; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D002762:Cholecalciferol; D014212:Tretinoin
Blood. 1999 May 15;93(10):3167-215
10233871
Blood. 1993 Oct 1;82(7):1949-53
8400247
Nat Med. 2004 Dec;10(12):1329-35
15531890
Genes Dev. 2000 Jan 15;14(2):121-41
10652267
Blood. 2000 Mar 1;95(5):1541-50
10688806
Trends Cell Biol. 2000 Jul;10(7):290-5
10856932
Mol Cell. 2000 May;5(5):811-20
10882117
Mol Cell. 2000 May;5(5):821-30
10882118
Blood. 2000 Aug 15;96(4):1531-7
10942402
Science. 1999 Sep 3;285(5433):1569-72
10477521
Nature. 1999 Nov 4;402(6757):93-6
10573424
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14807-12
10611294
Genes Dev. 1999 Dec 15;13(24):3198-208
10617569
Genes Dev. 1999 Dec 15;13(24):3209-16
10617570
J Biol Chem. 2000 Jan 7;275(1):651-6
10617663
Br J Haematol. 1995 Apr;89(4):805-11
7772516
Cancer Res. 1996 Jul 1;56(13):2945-8
8674046
Blood. 1996 Oct 15;88(8):2826-32
8874178
EMBO J. 1996 Sep 16;15(18):4949-58
8890168
Blood. 1997 Jun 15;89(12):4282-9
9192750
Science. 1997 Nov 7;278(5340):1059-64
9353180
Cancer Res. 1998 Jan 1;58(1):14-9
9426049
Nat Genet. 1998 Feb;18(2):126-35
9462740
Nature. 1998 Feb 19;391(6669):811-4
9486654
Nature. 1998 Feb 19;391(6669):815-8
9486655
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10860-5
9724795
Blood. 1998 Oct 1;92(7):2244-51
9746761
Mol Cell Biol. 1998 Dec;18(12):7176-84
9819404
Mol Cell Biol. 1998 Dec;18(12):7185-91
9819405
Cancer Res. 2001 Jan 1;61(1):2-7
11196162
J Biol Chem. 2001 Jan 12;276(2):1317-25
11038364
Methods Enzymol. 2001;332:36-49
11305111
Mol Cell Biol. 2001 Nov;21(21):7172-82
11585900
Oncogene. 2001 Oct 29;20(49):7257-65
11704854
Science. 2002 Feb 8;295(5557):1079-82
11834837
Oncogene. 2002 May 13;21(21):3445-58
12032781
Nat Med. 2002 Jul;8(7):743-50
12091906
Science. 2002 Jul 5;297(5578):63-4
12098689
Science. 2002 Jul 5;297(5578):102-4
12098700
Semin Cancer Biol. 2002 Oct;12(5):331-7
12191632
Blood. 2002 Oct 15;100(8):2989-95
12351412
J Exp Med. 2002 Nov 4;196(9):1227-40
12417632
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17107-12
12475933
Nat Rev Cancer. 2003 Feb;3(2):89-101
12563308
Nat Med. 2003 Apr;9(4):383-6
12669051
Stroke. 2003 May;34(5):1304-10
12677018
Nat Rev Mol Cell Biol. 2003 Sep;4(9):690-9
14506472
Cell. 2003 Oct 31;115(3):305-18
14636558
J Clin Invest. 2003 Dec;112(11):1751-61
14660751
Mol Cell Biol. 2004 Feb;24(3):1033-43
14729951
Cell. 2004 Feb 20;116(4):511-26
14980219
J Exp Med. 2004 Apr 19;199(8):1163-74
15096541
Blood. 1991 Mar 1;77(5):1080-6
1995093
EMBO J. 1992 Feb;11(2):629-42
1311253
Cancer Res. 1992 Jul 1;52(13):3687-92
1319828
Blood. 1992 Jul 15;80(2):492-7
1320955
Cell. 1993 Aug 13;74(3):423-31
8394219